FOLD241220C15000
- 0.15
- 0.000.00%
Amicus Therapeutics Newsroom
J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Announces Target Price $17
Amicus Therapeutics Price Target Raised to $17.00/Share From $16.00 by JP Morgan
Amicus Therapeutics Analyst Ratings
J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating
A Quick Look at Today's Ratings for Amicus Therapeutics(FOLD.US), With a Forecast Between $15 to $21
Amicus Therapeutics: Strong Financial Performance and Strategic Advancements Drive Buy Rating
Amicus Therapeutics Is Maintained at Buy by Guggenheim
Cantor Fitzgerald Maintains Overweight on Amicus Therapeutics, Raises Price Target to $21
A Quick Look at Today's Ratings for Amicus Therapeutics(FOLD.US), With a Forecast Between $15 to $20
Amicus Therapeutics Analyst Ratings
Amicus Therapeutics: Strong Financial Performance and Growth Prospects Justify Buy Rating
TD Cowen Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
BofA Securities Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Raises Target Price to $15
Amicus Therapeutics Analyst Ratings
Amicus Therapeutics Is Maintained at Overweight by Morgan Stanley
Morgan Stanley Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Cuts Target Price to $18
Amicus Therapeutics Analyst Ratings
Jefferies Initiates Amicus Therapeutics(FOLD.US) With Buy Rating, Announces Target Price $18
Amicus Therapeutics Analyst Ratings
J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Cuts Target Price to $16